Current Hematologic Malignancy Reports Current Hematologic Malignancy Reports RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms
AbstractPurpose of ReviewThrombosis remains a leading cause of morbidity and mortality in BCR/ABL negative myeloproliferative neoplasms (MPN). Circulating blood cells are both increased in quantity and qualitatively abnormal in MPN, resulting in an increased thrombotic risk. Herein, we review recently elucidated mechanisms of MPN thrombosis and discuss implications of drugs currently under investigation for MPN.Recent FindingsRecent studies highlight that inJAK2V617F granulocytes and platelets, thrombo-inflammatory genes are upregulated. Furthermore, inJAK2V617F granulocytes, protein expression of integrin CD11b, tissue fa...
Source: Current Hematologic Malignancy Reports - April 19, 2021 Category: Hematology Source Type: research

Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma
AbstractPurpose of ReviewWith rapid advances in the therapeutic landscape and biological insights in multiple myeloma, it is critical to identify and strategically manage high-risk patients to achieve best outcomes with currently available drugs. The purpose of this review is to summarize the management of high-risk myeloma with a focus on recent advances in the field.Recent FindingsThe most widely accepted definition of “high-risk” is theRevised International Staging System (R-ISS) stage 3 disease, which includes high tumor burden (ISS stage 3)and high-risk FISH cytogenetics or an elevated lactate dehydrogenase level....
Source: Current Hematologic Malignancy Reports - April 19, 2021 Category: Hematology Source Type: research

Goal of a “Good Death” in End-of-Life Care for Patients with Hematologic Malignancies—Are We Close?
AbstractPurpose of ReviewThe medical field has a critical role not only in prolonging life but also in helping patients achieve a good death. Early studies assessing end-of-life quality indicators to capture if a good death occurred demonstrated low rates of hospice use and high rates of intensive healthcare utilization near death among patients with hematologic malignancies, raising concerns about the quality of death. In this review, we examine trends in end-of-life care for patients with hematologic malignancies to determine if we are close to the goal of a good death.Recent FindingsSeveral cohort studies show that pati...
Source: Current Hematologic Malignancy Reports - April 16, 2021 Category: Hematology Source Type: research

When to Use Targeted Therapy for the Treatment of Follicular Lymphoma
AbstractPurpose of ReviewFollicular lymphoma is a common indolent non-Hodgkin lymphoma with survival improving in the modern era. Despite favorable responses and improving remission duration, FL remains largely incurable with patterns of relapsing and remitting disease with many patients requiring multiple lines of therapy. As our understanding of the malignant B-cell biology evolves, more targeted therapies have emerged for the treatment of follicular lymphoma.Recent FindingsTargeted therapies entering the treatment landscape of follicular lymphoma include lenalidomide in combination with rituximab based on the randomized...
Source: Current Hematologic Malignancy Reports - April 2, 2021 Category: Hematology Source Type: research

Goal of a “Good Death” in End-of-Life Care for Patients with Hematologic Malignancies—Are We Close?
AbstractPurpose of ReviewThe medical field has a critical role not only in prolonging life but also in helping patients achieve a good death. Early studies assessing end-of-life quality indicators to capture if a good death occurred demonstrated low rates of hospice use and high rates of intensive healthcare utilization near death among patients with hematologic malignancies, raising concerns about the quality of death. In this review, we examine trends in end-of-life care for patients with hematologic malignancies to determine if we are close to the goal of a good death.Recent FindingsSeveral cohort studies show that pati...
Source: Current Hematologic Malignancy Reports - April 1, 2021 Category: Hematology Source Type: research

Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches
AbstractPurpose of ReviewAcute myeloid leukemia (AML) is an aggressive malignancy of the bone marrow that has a poor prognosis with traditional cytotoxic chemotherapy, especially in elderly patients. In recent years, small molecule inhibitors targeting AML-associatedIDH1,IDH2, andFLT3 mutations have been FDA approved. However, the majority of AML cases do not have a targetable mutation. A variety of novel agents targeting both previously untargetable mutations and general pathways in AML are currently being investigated. Herein, we review selected new targeted therapies currently in early-phase clinical investigation in AM...
Source: Current Hematologic Malignancy Reports - April 1, 2021 Category: Hematology Source Type: research

MRD Assessment in Multiple Myeloma: Progress and Challenges
AbstractPurpose of ReviewOver the last decade, the development of effective treatment approaches for multiple myeloma (MM) has been associated with higher response rates and longer survival. In patients who achieve complete response, several high sensitivity techniques have been studied to assess minimal residual disease (MRD) and detect residual neoplastic cells within the bone marrow (by flow cytometry or molecular biology techniques) or outside the bone marrow (by imaging or circulating disease markers in the peripheral blood). This is of utmost importance, since residual disease can drive clinical relapse. This review ...
Source: Current Hematologic Malignancy Reports - April 1, 2021 Category: Hematology Source Type: research

The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond
AbstractPurpose of ReviewThe coronavirus disease 2019 (COVID-19) pandemic has had profound impacts upon scientific discourse in our field, most prominently through the abrupt transition of malignant hematology conferences to all-digital formats. These virtual components will likely be incorporated into future iterations of these conferences even as in-person attendance is reincorporated. In this review, we discuss ways in which usage of the social networking platform Twitter has expanded in the past year during virtual conferences as a method to facilitate —and, in some ways, democratize—information flow and profession...
Source: Current Hematologic Malignancy Reports - March 31, 2021 Category: Hematology Source Type: research

Evolution of Hematology Clinical Trial Adverse Event Reporting to Improve Care Delivery
AbstractPurpose of ReviewReporting of adverse events on hematology clinical trials is crucial to understanding the safety of standard treatments and novel agents. However, despite the importance of understanding toxicities, challenges in capturing and reporting accurate adverse event data exist.Recent FindingsCurrently, adverse events are reported manually on most hematology clinical trials. Especially on phase III trials, the highest grade of each adverse event during a reporting period is typically reported. Despite the effort committed to AE reporting, studies have identified underreporting of adverse events on hematolo...
Source: Current Hematologic Malignancy Reports - March 30, 2021 Category: Hematology Source Type: research

Targeted Therapies for Follicular Lymphoma
AbstractFollicular lymphoma (FL) is the 2nd most common lymphoma in the USA/Western Europe. While incurable, the majority of patients are able to survive at least a decade with this disease. Response duration though varies, and subset of patients will relapse within 24 months of initial therapy (POD24). These patients have shortened survival compared to those who achieve more durable responses. Treatment interventions for patients are varied and include observation, radiation, or systemic therapies. Treatment outcomes have improved considerably over the last several decades with the introduction of new agents such as the C...
Source: Current Hematologic Malignancy Reports - March 22, 2021 Category: Hematology Source Type: research

Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches
AbstractPurpose of ReviewAcute myeloid leukemia (AML) is an aggressive malignancy of the bone marrow that has a poor prognosis with traditional cytotoxic chemotherapy, especially in elderly patients. In recent years, small molecule inhibitors targeting AML-associatedIDH1,IDH2, andFLT3 mutations have been FDA approved. However, the majority of AML cases do not have a targetable mutation. A variety of novel agents targeting both previously untargetable mutations and general pathways in AML are currently being investigated. Herein, we review selected new targeted therapies currently in early-phase clinical investigation in AM...
Source: Current Hematologic Malignancy Reports - March 18, 2021 Category: Hematology Source Type: research

Antibody-Based Treatment Approaches in Multiple Myeloma
AbstractPurpose of ReviewThe field of multiple myeloma treatment has entered a new era with antibody-based approaches in clinical practice. In this review, we focus on the clinical approaches of utilizing antibody-based modality, specifically monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell antibodies in the treatment of multiple myeloma.Recent FindingsThree monoclonal antibodies (daratumumab, isatuximab, elotuzumab) and one anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (belantamab mafodotin) have been approved by the FDA in the last 5 years for the treatment of multiple myeloma. There...
Source: Current Hematologic Malignancy Reports - March 17, 2021 Category: Hematology Source Type: research

AYA Considerations for Aggressive Lymphomas
AbstractPurpose of ReviewLymphoma is the one of the most common cancer diagnoses among adolescents and young adults (AYAs) aged 15 –39. Despite significant advances in outcomes observed in older adults and younger children, improvements in AYAs have lagged behind. The reasons for this are likely multifactorial including disparities in access to health insurance, low rates of enrollment to clinical trials, potential difference s in disease biology, and unique psychosocial challenges. Here we will review Hodgkin lymphoma (HL) and primary mediastinal B cell lymphoma (PMBCL), two of the most common aggressive lymphomas that ...
Source: Current Hematologic Malignancy Reports - March 16, 2021 Category: Hematology Source Type: research

Treatment advances for pediatric and adult onset neoplasms with monocytosis
AbstractPurpose of reviewFor decades, the management of chronic myelomonocytic leukemia (CMML) or juvenile myelomonocytic leukemia (JMML) has been largely inextricable from myelodysplastic syndromes (MDS), myeloproliferative neoplasms, and acute myeloid leukemia. Hallmarks of these diseases have been the emergence of unique genomic signatures and discouraging responses to available therapies. Here, we will critically examine the current options for management and review the rapidly developing opportunities based on advances in CMML and JMML disease biology.Recent findingsFew clinical trials have exclusively been done in CM...
Source: Current Hematologic Malignancy Reports - March 16, 2021 Category: Hematology Source Type: research

Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings
Purpose of ReviewBased on personal experiences, recommendations for physicians treating patients with multiple myeloma (MM) in low- and middle-income countries (LMICs) are proposed.Recommendations(1) Implement strategies to keep the patient in the best possible condition for the longest time, in addition to focusing on ways to avoid financial toxicity; (2) if lenalidomide is unavailable, start treatment with thalidomide and dexamethasone, include, if possible, bortezomib; (3) conduct an outpatient-based autologous stem cell transplantation (ASCT) in all eligible patients; (4) use thalidomide as post-ASCT maintenance treatm...
Source: Current Hematologic Malignancy Reports - March 11, 2021 Category: Hematology Source Type: research